Acumen pharmaceuticals presents patient experience and biomarker data from phase 1 intercept-ad study at the alzheimer's association international conference (aaic®) 2024

Newton, mass., july 28, 2024 (globe newswire) -- acumen pharmaceuticals, inc. (nasdaq: abos), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (aΒos) for the treatment of alzheimer's disease (ad), today announced new findings from its phase 1 intercept-ad study of sabirnetug (acu193). the research highlights the experiences of patients in the clinical trial to inform development of future trials, biomarker data to support sabirnetug's mechanism of action, and an ultra-sensitive method of measuring small amounts of sabirnetug in cerebrospinal fluid (csf). the posters will be presented at the alzheimer's association international conference (aaic®) 2024 taking place in philadelphia and online from july 28-aug. 1, 2024.
ABOS Ratings Summary
ABOS Quant Ranking